Neoplasms

Blood and Lymph Conditions

All Conditions

Heart and Blood Diseases

Immune System Diseases

Nutritional and Metabolic Diseases

Nervous System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Diseases and Abnormalities at or Before Birth

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Rare Diseases

Leukemia

Multiple Myeloma

Neoplasms, Plasma Cell

Amyloidosis

Polyneuropathies

Monoclonal Gammopathy of Undetermined Significance

Smoldering Multiple Myeloma

Glomerulonephritis, Membranous

Leukemia, Plasma Cell

Endocrine System Diseases

POEMS Syndrome

Castleman Disease

Cryoglobulinemia

Syndrome

Paraproteinemias

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Proteostasis Deficiencies

Metabolic Diseases

Peripheral Nervous System Diseases

Neuromuscular Diseases

Hypergammaglobulinemia

Precancerous Conditions

Lymphatic Diseases

Skin Diseases

Skin Diseases, Vascular

Congenital Abnormalities

Abnormalities, Multiple

Membranous Nephropathy

Plasma Cell Leukemia

Unicentric Castleman Disease

Light Chain Deposition Disease

No intervention

Bo Tang, PhD

Yujun Dong, M.D.

Yangliu Li

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

Primary

1. To establish a prospective cohort of patients with PCDs in PKUFH.
2. To dynamically analyze the relation between MRD status and prognosis, and the possible role of TME in PCD patients.

Secondary To collect peripheral blood, bone marrow aspirate and urine samples from PCD patients for future study, such as the tumor clone selection and evolution.

OUTLINE: PCD patients enrolled in this study will be assessed at baseline, clinical and laboratory data and biological samples be collected. Follow-up will be done at the 1, 3, 6, 12 months and then yearly after treatment.

Peripheral blood, bone marrow aspirate and urine samples will be banked for future research involving adults with PCDs.

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH

To measure the treatment response in the cohort study of PCDs in PKUFH.The treatment response is done according to the criteria of the International Myeloma Working Group (IWMG) of 2016.

Peking University First Hospital

chief of department of hematology

Amy Garrett, MA

Kirsten Nyrop, PhD

Sascha Tuchman, MD

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

OBJECTIVES:

Primary

1. To create a Registry (to be called the PCD Registry) of PCD patients
2. To have participating patients complete an assessment at enrollment and to repeat the assessment longitudinally over time.

Secondary

1. To gather information, including patterns of patient care, that would lend support for future research in the PCD population. Specific research questions would be explored within separate IRB-reviewed protocols.
2. To bank blood samples for future research involving adults with PCD's, specifically examining p16INK4a and other markers to be specified in future, separate, IRB-approved protocols as specific research questions are identified.

OUTLINE: Patients complete an assessment at baseline and then longitudinally over time which involves a multi-dimensional inter-disciplinary evaluation of a patient's functional status (ability to live independently at home and in the community), co-morbid medical conditions, cognition, psychological status, social functioning and support, medication review, and nutritional status. Patients' medical records are also reviewed.

Blood samples will be banked for future research involving adults with PCDs, specifically examining p16INK4a and other markers to be specified in future, separate, IRB-reviewed protocols as specific research questions are identified.

Registry for Adults With Plasma Cell Disorders (PCD's)

Including patterns of patient care that would lend support for future research in patients with confirmed PCD's.

Done by measuring:

* percentage of patients contacted who consent to complete the assessment percentage of patients able to complete the self-administered portion of the assessment without assistance
* the length of time necessary to complete the assessment
* the variance and number of missing items
* the percentage of geriatric assessments that contain all three of the following items: Timed Up and Go Assessment, Blessed Orientation-Memor Concentration Test, and the healthcare professional-rated Karnofsky performance status.

UNC Lineberger Comprehensive Cancer Center

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH	NCT05283993	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm...	No intervention	-	Peking University First Hospital
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH	NCT05283993	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu... Monoclonal Gamm... Monoclonal Gamm... Monoclonal Gamm...	No intervention	-	Peking University First Hospital
Registry for Adults With Plasma Cell Disorders (PCD's)	NCT03717844	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu...		18 Years -	UNC Lineberger Comprehensive Cancer Center
Registry for Adults With Plasma Cell Disorders (PCD's)	NCT03717844	Multiple Myelom... Amyloidosis Cryoglobulinemi... Castleman's Dis... Light Chain Dep... Heavy Chain Dep... Polyneuropathy ... Smoldering Mult... Plasma Cell Leu...		18 Years -	UNC Lineberger Comprehensive Cancer Center

Spots Global Cancer Trial Database for cryoglobulinemia